

European Heart Journal

Volume 45 No. 35 September 2024

ISSUE @ A GLANCE

 The fascinating story of lipid-lowering drugs, sodium-glucose co-transporter 2 inhibitors and GLP1-R agonists: new light shed on their beneficial effects

F. Crea 3187

CardioPulse

Multi-stakeholder workshop on reducing population-wide dietary sodium intake in Nigeria

C. Obiezu-Umeh, M.D. Huffman, and D. Ojji 3192

The ESC Working Group on Cellular Biology of the Heart

C. Perrino, M. Pesce, and S.M. Davidson 3195

In memoriam: Akira Endo

A.L. Catapano, A. Pirillo, and L. Tokgözoglu 3199

Weekly Journal Scan

Weekly Journal Scan: an ounce of PREVENTion is worth more than a pound of stents

R. Vergallo and L. Galiuto 3201

FOCUS ISSUE ON DYSLIPIDAEMIAS, HEART FAILURE AND CARDIOMYOPATHIES

STATE OF THE ART REVIEW

 Artificial intelligence-enhanced patient evaluation: bridging art and science

E.K. Oikonomou and R. Khera 3204

META-ANALYSIS

Lipid lowering for prevention of venous thromboembolism: a network meta-analysis

I.T. Farmakis, K.C. Christodoulou, L. Hobohm, S.V. Konstantinides, and L. Valerio 3219

Editorial

From arteries to veins: the expanding role of lipid-lowering drugs in preventing thrombosis

S. Nopp, C. Ay, and I. Pabinger 3228

FAST TRACK – CLINICAL RESEARCH

 Sex differences in treatment of familial hypercholesterolaemia: a meta-analysis

I. Iatan, L.E. Akioyamen, I. Ruel, A. Guerin, L. Hales, T. Coutinho, L.R. Brunham, and J. Genest 3231

Editorial

Familial hypercholesterolaemia: need for equitable treatment in women and men

R.D. Santos 3251

 Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction:

a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials

S.J. Shah, K. Sharma, B.A. Borlaug, J. Butler, M. Davies, D.W. Kitzman, M.C. Petrie, S. Verma, S. Patel, K.M. Chinnakondapalli, M.N. Einfeldt, T.J. Jensen, S. Rasmussen, R. Asleh, T. Ben-Gal, and M.N. Kosiborod; for the STEP-HFpEF Trial Committees and Investigators 3254

Editorial

STEPping down diuretic therapy with semaglutide in obesity-related heart failure with preserved

ejection fraction: decongestion or disease modification?

J.W. Ostrominski, S. Chatur, and M. Vaduganathan 3270

CLINICAL RESEARCH



Post-capillary pulmonary hypertension in heart failure: impact of current definition in the PH-HF multicentre study

C. Fauvel, T. Damy, E. Berthelot, F. Bauer, J.-C. Eicher, P. de Groote, J.-N. Trochu, F. Picard, S. Renard, H. Bouvaist, D. Logeart, F. Roubille, O. Sitbon, and N. Lamblin

3274

Editorial

Pulmonary hypertension in heart failure: the good, the bad, and the ugly

S. Rosenkranz, M.M. Hooper, and B.A. Maron

3289

RAPID COMMUNICATIONS



Single-nucleus RNA sequencing identifies cell-type-specific effects of sodium-glucose co-transporter 2 inhibitors in human myocardial slices

K. Schmidt, M. Fuchs, N. Weber, C. Werlein, J.D. Schmitto, F. Ius, A. Ruhparwar, C. Bär, J. Fiedler, and T. Thum

3292

CARDIOVASCULAR FLASHLIGHTS



Pulsus alternans under left ventricular assist device in a patient with dilated cardiomyopathy and LMNA mutation

R. Sakai, T. Kashimura, and T. Inomata

3296

The role of natural compensatory mechanisms in complex congenital heart disease: haemodynamic evolution and clinical outcomes in a case of Cor triatriatum sinistrum syndrome

G. Yang, Y. Zhang, and Z. Liu

3297

CORRECTION

Correction to: Atherosclerosis in ancient mummified humans: the global HORUS study

3227



This paper is Editor's Choice and is available free online at <https://academic.oup.com/eurheartj>



Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



www.eurheartj.org